Nutrition · Explainer

What studies say about whether aspartame is bad for you

Regulatory assessments have not established a health risk from aspartame at permitted intake levels, although observational studies have reported associations with certain cancers without proving causation (JECFA, 2023; Debras et al., 2022). IARC classified aspartame as possibly carcinogenic to humans (Group 2B) based on limited evidence for liver cancer, while JECFA maintained its existing acceptable daily intake after reviewing the available evidence (IARC, 2024; JECFA, 2023).

The chemistry of aspartame is covered first, followed by the way food safety agencies set intake limits and the evidence on cancer, heart disease and body weight. International hazard and risk assessments, large population cohorts, a multicase-control study, lifetime animal feeding experiments and a guideline built on a systematic review supply the evidence. The final section separates findings from open questions.

Glass of dark diet cola with ice cubes next to white sweetener sachets and small tablets on a wooden table
A glass of iced diet cola beside sweetener sachets and tablets on a table Editorial illustration

What aspartame is and why some think it is bad for you

Manufacturers have used aspartame in reduced-calorie products since the 1980s, according to the IARC Working Group (2024). The FDA (2025) describes the molecule as a dipeptide, a pairing of aspartic acid with phenylalanine.

Doubt about its safety comes from two directions. An IARC panel placed aspartame in Group 2B, its hazard category for possible human carcinogens (IARC, 2024). Next came JECFA, an expert body that FAO and WHO run together, which saw no convincing evidence from animal or human data of harm after ingestion (JECFA, 2023).

The two verdicts are often read as a contradiction. In fact one panel asks whether a substance is capable of producing tumours at all, while the other asks whether the amounts people actually eat carry a measurable risk. The FDA (2025) reports that its scientists went through over a hundred toxicity studies.

How the body breaks down aspartame

Phenylalanine, aspartic acid and methanol

Aspartame does not reach the bloodstream intact. In humans and animals it is fully hydrolysed in the gut into three compounds: phenylalanine, aspartic acid and methanol (JECFA, 2023). EFSA (2014) notes that aspartame itself has never been detected in the blood or in any organ after ingestion.

Methanol draws the most attention. It makes up 10% of aspartame by weight, the IARC Working Group (2024) notes. At an intake equal to the ADI, aspartame would supply 1–10% of total methanol exposure, while methanol made inside the body accounts for more than 80%, according to an estimate cited by IARC (2024).

Blood levels tell a similar story. When volunteers took doses up to the current intake limit, plasma levels of these breakdown products did not rise (JECFA, 2023). Plasma phenylalanine stayed within normal after-meal levels in healthy people and was higher in carriers of one phenylketonuria gene, falling again within hours (IARC, 2024).

Why phenylketonuria is an exception

People born with phenylketonuria, or PKU, cannot metabolise phenylalanine normally. EFSA (2013) states that the safe intake limit does not apply to this group, because they must keep to a diet low in phenylalanine. The FDA (2025) advises anyone with this rare inherited disorder to avoid or limit aspartame. In Europe roughly 1 in 10,000 babies are born with PKU, with variation between populations (EFSA, 2014).

Labels carry this warning by law. Under EU food information rules, a product must state that it contains a source of phenylalanine when aspartame appears by name in the ingredients list (European Parliament and Council, 2011). When only the E number is listed, the required wording is contains aspartame (a source of phenylalanine) (European Parliament and Council, 2011). American federal rules require the statement PHENYLKETONURICS: CONTAINS PHENYLALANINE (Code of Federal Regulations, 1974).

How regulators set a safe intake limit

EFSA and FDA limits

Regulators express safety as an ADI, the intake per day they judge acceptable, and the FDA (2025) defines it as the quantity a person could safely eat every day across a whole lifetime. It is a regulatory limit, not a target.

EFSA completed a full re-evaluation in 2013. Its panel judged that the existing ADI, set at 40 mg for every kilogram a person weighs each day, protects the general population (EFSA, 2013). The review covered the 112 original documents submitted for authorisation in the early 1980s alongside newer work (EFSA, 2013).

Its experts ruled out a risk of aspartame damaging genes or inducing cancer (EFSA, 2013). Consumer exposure was estimated to be well below the ADI (EFSA, 2026).

American regulators use a different figure. The IARC Working Group (2024) notes that the US limit is 50 mg/kg of body weight, compared with 40 mg/kg per day in Europe.

The JECFA review of 2023

JECFA examined aspartame again alongside the IARC meeting. Its intake limit stayed unchanged at 0–40 mg per kilogram (JECFA, 2023).

The joint summary explains why the IARC label did not change that limit. IARC labels grade how solid the evidence of a cancer hazard is and say nothing about how large the danger is at any particular dose (JECFA, 2023). In JECFA wording (2023) the same human data fall short of convincing, its equivalent of what the cancer agency calls limited evidence. One regulator goes further: the FDA (2025) rejects the IARC view that the available research justifies the possible-carcinogen label for aspartame.

What studies show about aspartame and cancer

The IARC classification

IARC reviewed a large body of work. More than 7,000 references were screened and about 1,300 studies were made available to the working group (JECFA, 2023). For the human data, the panel weighed 12 prospective cohorts and 13 case-control studies, two of which it judged not informative (IARC, 2024).

The panel rated the human data as limited. The monograph found aspartame positively associated with hepatocellular carcinoma, the main type of liver cancer, which develops in the liver cells themselves. Only three studies, covering four cohorts of people who drank artificially sweetened beverages, were available on liver cancer (IARC, 2024). All three showed a positive association, but bias or confounding could not be ruled out (IARC, 2024).

The panel was not unanimous. A minority supported the higher Group 2A, but the Working Group overall did not (IARC, 2024).

Evidence from the NutriNet-Santé cohort

One large dataset comes from France. Debras and colleagues (2022) followed 102,865 adults in the NutriNet-Santé cohort between 2009 and 2021. Diet was recorded through repeated 24-hour records that included brand names of products (Debras et al., 2022).

Aspartame made up 58% of artificial sweetener intake in the group (Debras et al., 2022). During 708,905 person-years of follow-up, with a median of 7.7 years, 3,358 participants were diagnosed with cancer, among them 982 breast cancers, 403 prostate cancers and 2,023 obesity-related cancers (Debras et al., 2022).

For all cancers combined, higher aspartame consumers had a hazard ratio of 1.15, with a 95% confidence interval of 1.03 to 1.28, against non-consumers (Debras et al., 2022). The ratio was 1.22 for breast cancer and 1.15 for obesity-related cancers (Debras et al., 2022). A hazard ratio is relative, and the authors state that causal links cannot be established and that residual confounding cannot be fully excluded (Debras et al., 2022).

The cohort could not test the liver finding. There were too few cases to study liver, pancreatic or kidney cancer (Debras et al., 2022).

A Spanish case-control study pointed the other way. Palomar-Cros and colleagues (2023) compared 1,881 colorectal, 1,510 breast, 972 prostate, 351 stomach and 109 chronic lymphocytic leukaemia cases with 3,629 population controls. Neither aspartame nor other artificial sweeteners showed associations with cancer as a whole (Palomar-Cros et al., 2023).

Animal studies and their limits

The strongest claims come from rats. Soffritti and colleagues (2006) fed aspartame to Sprague-Dawley rats, 100–150 per sex in each group, at concentrations from 0 to 100,000 ppm until natural death. The authors reported carcinogenic effects even at a calculated dose of 20 mg/kg of body weight, below the current intake limit (Soffritti et al., 2006).

Agencies that examined this work found weaknesses. IARC (2024) raised serious questions about the design, conduct, interpretation and reporting of every one of these rodent studies. In the two studies that exposed rats before birth, no adjustment was made for litter effects (JECFA, 2023). JECFA (2023) identified limitations in all 12 oral carcinogenicity studies it reviewed.

Data access was another problem. When the FDA asked the laboratory for complete study reports, it received only some data, according to the agency’s historical timeline (FDA, 2023). After assessing the rat findings, EFSA experts saw no sign of aspartame being genotoxic or carcinogenic and no reason to revise the ADI (EFSA, 2026).

Study

Design and size

What was measured

Main finding

IARC (2024)

12 cohorts and 13 case-control studies

Hazard classification

Group 2B; human data on liver cancer rated limited

Debras et al. (2022), PLOS Medicine

Cohort of 102,865 adults

Cancer incidence by aspartame intake

HR 1.15 for cancer overall

Palomar-Cros et al. (2023)

Cases in five cancer sites, 3,629 controls

Cancer by sweetener intake

No associations overall

Debras et al. (2022), BMJ

Cohort of 103,388 adults

Cardiovascular events

HR 1.17 for cerebrovascular events

Soffritti et al. (2006)

Rats, 100–150 per sex per group

Tumours after lifetime feeding

Effects reported at a calculated 20 mg/kg

Note: the human studies are observational and show associations, not causes, and the rat study used calculated doses. Hazard ratios are relative measures and give no absolute risk for an individual.

Other health outcomes linked to sweeteners

Heart disease and stroke

A second analysis of the French cohort looked at the heart and brain. Published in the BMJ, Debras and colleagues (2022) followed 103,388 participants for 904,206 person-years. Aspartame intake was associated with cerebrovascular events, with a hazard ratio of 1.17 per unit of log-transformed intake and incidence rates of 186 versus 151 per 100,000 person-years in higher consumers and non-consumers (Debras et al., 2022).

The 777 cerebrovascular events included 203 strokes and 598 transient ischaemic events (Debras et al., 2022). Transient events are diagnosed with less certainty (Debras et al., 2022). No causal relation can be established from a single observational study, the authors write (Debras et al., 2022). JECFA (2023) reviewed the cerebrovascular and type 2 diabetes associations from this cohort and did not find them convincing.

Replacing sugar did not appear to help either. In the same BMJ analysis, substituting artificial sweeteners for added sugars showed no benefit for cardiovascular risk, with a hazard ratio of 1.00 (Debras et al., 2022). Both the BMJ and the PLOS Medicine papers draw on NutriNet-Santé, so they come from one cohort (Debras et al., 2022).

Body weight and the WHO guideline

The WHO looked at sweeteners as a group. Its 2023 guideline suggests that non-sugar sweeteners not be used to control weight or reduce the risk of noncommunicable diseases, a conditional recommendation (WHO, 2023). The evidence behind it was of low certainty overall (WHO, 2023).

Several points narrow its scope. The guideline is based on use within the ADI and does not change safe or maximal intake levels (WHO, 2023). It does not apply to people with existing diabetes (WHO, 2023).

In long-term cohorts, higher sweetener intake was associated with type 2 diabetes and cardiovascular disease but not with overall cancer incidence (WHO, 2023). Evidence was too thin to make recommendations for any single sweetener, aspartame included (WHO, 2023).

Behind the guideline sits a systematic review by Rios-Leyvraz and Montez (2022) covering 283 studies. In case-control studies, non-sugar sweetener intake as a whole was associated with 31% higher odds of bladder cancer (Rios-Leyvraz and Montez, 2022). Other cancer associations, higher for the larynx and lower for the lung and ovary, each rested on one or two studies and must be interpreted with caution (Rios-Leyvraz and Montez, 2022).

The authors noted that reverse causation, with people at higher risk switching to sweeteners, may explain some cohort associations (Rios-Leyvraz and Montez, 2022). Appetite and weight depend on many dietary factors, as studies on protein and satiety also show.

What is proven about aspartame and what is not

Aspartame has not been shown to harm people at intakes within the regulatory limit, but the studies in people are observational and partly contradictory. The signals that exist come from a small number of cohorts.

The IARC Group 2B label rests on limited human data, while JECFA kept its intake limit because the same human data were not convincing (IARC, 2024; JECFA, 2023).

Some facts are settled. Aspartame is broken down in the gut into phenylalanine, aspartic acid and methanol, and the ADI does not apply to people with phenylketonuria (JECFA, 2023; EFSA, 2013). Regulators in the EU and the US kept their limits after reviewing the evidence (EFSA, 2013; FDA, 2025).

Other findings depend on how the data are read. Intake was usually self-reported, for example through a food frequency questionnaire in the Spanish study (Palomar-Cros et al., 2023).

In the reviewed studies, reverse causality, chance, bias and confounding by lifestyle or diet could not be completely ruled out (JECFA, 2023). No specific cancer type shows a consistent link (JECFA, 2023). For cancers other than liver, the data were not informative or consistent enough for a conclusion (IARC, 2024).

Intakes in the cohorts were modest. All NutriNet-Santé participants stayed below the ADI for aspartame, so the study says nothing about intakes near the limit (Debras et al., 2022). Nutrition questions of this kind, where diet and cancer are linked through observational data, are also examined in selenium and cancer prevention.

Several questions remain open. The mechanistic evidence is suggestive, with oxidative stress seen in experimental systems but nothing comparable measured in exposed people (IARC, 2024). The French authors call for replication in other large cohorts and for experimental work on mechanisms (Debras et al., 2022). Assessing additives and contaminants in food relies on measurement over long periods, a theme also seen in early biomonitoring of DDT.

Frequently asked questions

Did the WHO say that aspartame causes cancer?

No. IARC, the WHO cancer agency, classed aspartame as possibly carcinogenic on limited evidence for liver cancer, which is a hazard label rather than a measure of risk (IARC, 2024; JECFA, 2023). The joint FAO and WHO food additives committee, JECFA, reaffirmed the intake limit of 0–40 mg/kg of body weight in the same year (JECFA, 2023).

How can you tell if a product contains aspartame?

In the EU, aspartame must appear on the label either by name or by its E number, E 951 (EFSA, 2026). Products with sweeteners must also carry the words with sweetener(s) next to the name of the food (European Parliament and Council, 2011). A phenylalanine statement on the label is another sign that aspartame is present.

Why do some labels warn about phenylalanine?

It is meant for people with phenylketonuria. For them, the safe intake limit does not apply (EFSA, 2013). Aspartame is broken down in the gut into phenylalanine, aspartic acid and methanol (JECFA, 2023). US rules require the statement PHENYLKETONURICS: CONTAINS PHENYLALANINE on the label (Code of Federal Regulations, 1974).

Is aspartame safer than sugar?

The evidence does not answer this directly. In a large French cohort, replacing added sugars with artificial sweeteners showed no benefit for cardiovascular risk (Debras et al., 2022). The WHO suggests that non-sugar sweeteners not be used for weight control, a conditional recommendation based on low-certainty evidence (WHO, 2023).

Does aspartame change gut bacteria?

The evidence is unclear. Studies in animals and humans have suggested that aspartame may alter the gut microbiome, but the results are inconsistent (JECFA, 2023). Aspartame is fully broken down in the gut, and in human studies at doses up to the ADI, plasma levels of its breakdown products did not rise (JECFA, 2023).

Sources

  1. IARC Working Group on the Identification of Carcinogenic Hazards to Humans. Aspartame. In: Aspartame, Methyleugenol, and Isoeugenol. IARC Monographs on the Identification of Carcinogenic Hazards to Humans, Volume 134. Lyon: International Agency for Research on Cancer; 2024. ISBN 978-92-832-0173-1.
  2. World Health Organization, International Agency for Research on Cancer and Food and Agriculture Organization of the United Nations. Summary of findings of the evaluation of aspartame at the International Agency for Research on Cancer (IARC) Monographs Programme’s 134th Meeting, and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) 96th meeting. Geneva: WHO; 14 July 2023.
  3. Debras C, Chazelas E, Srour B, et al. Artificial sweeteners and cancer risk: results from the NutriNet-Santé population-based cohort study. PLOS Medicine. 2022;19(3):e1003950. DOI 10.1371/journal.pmed.1003950.
  4. Palomar-Cros A, Straif K, Romaguera D, et al. Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain). International Journal of Cancer. 2023;153(5):979–993. DOI 10.1002/ijc.34577.
  5. Debras C, Chazelas E, Sellem L, et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ. 2022;378:e071204. DOI 10.1136/bmj-2022-071204.
  6. Soffritti M, Belpoggi F, Degli Esposti D, et al. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environmental Health Perspectives. 2006;114(3):379–385. DOI 10.1289/ehp.8711.
  7. European Food Safety Authority. EFSA completes full risk assessment on aspartame and concludes it is safe at current levels of exposure. News story, 10 December 2013. https://efsa.europa.eu/en/press/news/131210
  8. European Food Safety Authority. EFSA explains the safety of aspartame. Parma: EFSA; 2014. ISBN 978-92-9199-578-3. DOI 10.2805/54386.
  9. European Food Safety Authority. Aspartame. Topic page, last reviewed 10 September 2026. https://www.efsa.europa.eu/en/topics/topic/aspartame
  10. U.S. Food and Drug Administration. Aspartame and other sweeteners in food. Content current as of 27 February 2025. https://fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food
  11. U.S. Food and Drug Administration. Timeline of selected FDA activities and significant events addressing aspartame. Content current as of 30 May 2023. https://fda.gov/food/food-additives-petitions/timeline-selected-fda-activities-and-significant-events-addressing-aspartame
  12. Code of Federal Regulations. Title 21, Section 172.804 Aspartame. 39 FR 27319, 26 July 1974, as amended. https://ecfr.gov/current/title-21/section-172.804
  13. European Parliament and Council of the European Union. Regulation (EU) No 1169/2011 on the provision of food information to consumers, Annex III. Official Journal of the European Union. 2011;L 304:18–63.
  14. World Health Organization. Use of non-sugar sweeteners: WHO guideline. Geneva: WHO; 2023. ISBN 978-92-4-007361-6.
  15. Rios-Leyvraz M, Montez J. Health effects of the use of non-sugar sweeteners: a systematic review and meta-analysis. Geneva: World Health Organization; 2022. ISBN 978-92-4-004642-9.
Elias R. Westbrook

Elias R. Westbrook — author

Elias R. Westbrook is academic background in human nutrition and nutritional sciences, with a focus on food composition, nutrient intake, dietary patterns, and the relationship between foods and nutritional health. For Cabdirect, this persona is intended to co...

This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.

Related

About this section